Table 3.
Study | Interventions | Net benefit | Net cost | ICER, key conclusions and uncertainty |
Boath et al 28 | Psychiatric day hospital vs routine primary care | 14 more women recovered in the intervention group. | The intervention was £53 824 (p<0.001) more expensive than routine care. | £3843 per each additional recovery. The net cost is sensitive to inclusion primary care and medication costs, increasing to £56 865. Possibly cost-effective |
Petrou et al 29 | Counselling and support from health visitors vs usual care | The intervention group depressed for 2.14 weeks fewer (over 18 months) than the control group—this was not statistically significant (p=0.41). | The intervention group costs were £189 higher, although this was not significant (95% CI −£843 to £1237). |
£68 per month of depression avoided. Possibly, a small improvement in outcomes for a small cost. Possibly cost-effective |
Morrell et al 30 |
Screening and talking therapy (CBA or PCA) delivered by health visitor vs usual care | EPDS score at 6 months was 0.9 lower (p<0.001) for those randomised to an intervention group. QALY gain of 0.002 (95% CI −0.001 to 0.005) associated with the intervention. | There was a non-significant net-saving of £26 (95% CI −£100 to £47) for women in the intervention groups. | Improved outcomes with comparable costs. No ICER reported because of negative net cost. CBA appears to be more cost-effective than PCA. Subgroup analysis of ’at-risk' women: 6-month EPDS score 2.1 lower (p=0.002). Analysis of imputed data: QALY gain increased to 0.003 (95% CI 0.001 to 0.006) and net cost saving increased to £47 (95% CI −£68 to −£4), both reaching statistical significance (£15 666/QALY). Highly likely to be cost-effective |
Stevenson et al 31 |
Group CBT vs usual care | Intervention associated with a QALY gain of 0.039 (PSA results). | £1568 net cost of providing gCBT (PSA results). | £39 875 per QALY gained. Intervention is not likely to be cost-effective at accepted thresholds. More research is needed to address the level of uncertainty. Not likely to be cost-effective |
Dukhovny et al 35 |
Telephone-based peer support vs usual care | 0.1116 more cases of postnatal depression avoided at 12 weeks in the intervention group. | £755 net cost associated with intervention (p<0.001). | £6768 per case of postnatal depression avoided. The ICER is within the range of other postnatal depression interventions. Possibly cost-effective |
Ride et al 34 |
Psychoeducational programme vs usual care | Comparable outcomes both in terms of prevalence of mental health conditions (p=0.883) and QALYs (p=0.967). | £167 net cost associated with the intervention, although this was not statistically significant (p=0.333). | £21 987/QALY; £92 per %-point reduction in 30-day prevalence of postnatal mental health disorders. The probability the intervention if cost-effective is 0.55 at a willingness to pay threshold of A$ 55 000 (approximately £30 000–£35 000)—more research is needed to reduce uncertainty. Multiple imputation of missing data increased ICER to £27 042/QALY. Possibly cost-effective |
Grote et al 32 |
Collaborative care for depression vs usual care | More depression-free days over 18 months for the intervention group:
|
Significant net cost associated with the intervention:
|
If a depression-free day is valued at US$20 (approximately £13):
|
Wilkinson et al 33 |
Psychiatrist-supported general practitioner screening and treating postpartum depression and psychosis | 29 more healthy women in the intervention group, equating to a total of 21.43 additional QALYs over 2 years. | Total additional cost associated with the intervention £185 173. | £8642 per QALY gained, £6350 per remission achieved, £588 per additional healthy woman. Likely to be cost-effective |
Currency conversion and inflation rates used are reported in online supplementary table S4.
CBA, cognitive behavioural approach; CBT, cognitive behavioural therapy; EPDS, Edinburgh Postnatal Depression Scale; PCA, person-centred approach; QALY, quality-adjusted life year; RCT, randomised controlled trial.